All Stories

  1. Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States

    Article • Journal of Medical Economics, April 2019, Taylor & Francis

    Frank Liu, Raquel Aguiar-Ibáñez

  2. An indirect treatment comparison of the efficacy of pembrolizumab versus competing regimens for the adjuvant treatment of stage III melanoma

    Article • Journal of Drug Assessment, January 2019, Taylor & Francis

    Raquel Aguiar-Ibáñez, Frank Liu

  3. Treatment patterns and outcomes for patients with advanced melanoma in US oncology clinical practices

    Article • Future Oncology, September 2018, Future Medicine

    Frank Liu

  4. Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment

    Article • Patient Preference and Adherence, August 2017, Dove Medical Press

    Frank Liu